Niels Janssen

Company: Roche

Job title: Group Head DMPK/PD

Seminars:

Development of Next Generation CNS Drugs: Trontinemab, an Anti-Amyloid Beta Brainshuttle Antibody 3:15 pm

Developing “Brainshuttle”, a versatile platform to enhance brain delivery of therapeutic proteins and other cargos across the blood brain barrier via receptor mediated transcytosis Showcasing translational strategies and learnings from the Brainshuttle antibody fusion trontinemab: The journey from mice to patients, towards a new generation of Amyloid beta lowering therapiesRead more

day: Conference Day Two